Clonal analysis of HIV-1 genotype and function associated with virologic failure in treatment-experienced persons receiving maraviroc: Results from the MOTIVATE phase 3 randomized, placebo-controlled trials.
Detailed clonal phenotypic/genotypic analyses explored viral-escape mechanisms during maraviroc-based therapy in highly treatment-experienced participants from the MOTIVATE trials. To allow real-time assessment of samples while maintaining a blind trial, the first 267 enrolled participants were sele...
Main Authors: | Marilyn Lewis, Julie Mori, Jonathan Toma, Mike Mosley, Wei Huang, Paul Simpson, Roy Mansfield, Charles Craig, Elna van der Ryst, David L Robertson, Jeannette M Whitcomb, Mike Westby |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2018-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0204099 |
Similar Items
-
Incidence of CXCR4 tropism and CCR5-tropic resistance in treatment-experienced participants receiving maraviroc in the 48-week MOTIVATE 1 and 2 trials
by: Becky Jubb, et al.
Published: (2019-12-01) -
Maraviroc – a CCR5 antagonist for the treatment of HIV-1 infection
by: Elna eVan Der Ryst
Published: (2015-06-01) -
V3-Loop genotypes do not predict maraviroc susceptibility of CCR5-tropic virus or clinical response through week 48 in HIV-1–infected, treatment-experienced persons receiving optimized background regimens
by: ME Lewis, et al.
Published: (2021-07-01) -
Highly prevalent Russian HIV-1 V3-loop sequence variants are susceptible to maraviroc
by: ME Lewis, et al.
Published: (2021-06-01) -
High Virologic Failure Rates with Maraviroc-Based Salvage Regimens Among Indian Patients: A Preliminary Analysis—Maraviroc Effectiveness in HIV-1 Subtype C
by: Sanjay Pujari MD, et al.
Published: (2018-02-01)